Maintaining Investments in New Innovation Act

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1672 Introduced in House (IH)]

<DOC>

119th CONGRESS
  1st Session
                                H. R. 1672

   To amend title XI of the Social Security Act to protect access to
                   genetically targeted technologies.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 27, 2025

 Mr. Davis of North Carolina (for himself, Mr. Joyce of Pennsylvania,
  Mr. Gottheimer, Ms. Tenney, Mr. Yakym, Mr. Morelle, Mr. Hudson, Mr.
   Bean of Florida, Mrs. Miller-Meeks, Mr. Allen, Ms. Van Duyne, Mr.
 Peters, Mr. Moore of Utah, and Mr. Crenshaw) introduced the following
 bill; which was referred to the Committee on Energy and Commerce, and
  in addition to the Committee on Ways and Means, for a period to be
subsequently determined by the Speaker, in each case for consideration
  of such provisions as fall within the jurisdiction of the committee
                               concerned

_______________________________________________________________________

                                 A BILL

   To amend title XI of the Social Security Act to protect access to
                   genetically targeted technologies.

    Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Maintaining Investments in New
Innovation Act''.

SEC. 2. AMENDMENT TO DEFINITION OF QUALIFYING SINGLE SOURCE DRUG.

    Section 1192(e) of the Social Security Act (42 U.S.C. 1320f-1(e))
is amended--
            (1) in paragraph (1)(A)(ii), by inserting ``(or, in the
        case of an advanced drug product (as defined in paragraph (4)),
        11 years)'' after ``7 years''; and
            (2) by adding at the end the following new paragraph:
            ``(4) Advanced drug product defined.--For purposes of
        paragraph (1)(A)(ii), the term `advanced drug product' means a
        drug that incorporates or utilizes a genetically targeted
        technology (as defined in section 529A(c)(2) of the Federal
        Food, Drug, and Cosmetic Act) that may result in the modulation
        (including suppression, up-regulation, or activation) of the
        function of a gene or its associated gene product.''.
                                 <all>